Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 8/20 | 0.64 |
| ▸ | CDK8 | P49336 | 4/20 | 0.63 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.63 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | SGK1 | O00141 | 3/20 | 0.54 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19661650 | 0.88 | GSK3B (0.52) | AXLCDK8TNIKGSK3BSGK1 | |
| SCHEMBL857279 | 0.86 | KMT2A (0.60) | AXLCDK8TNIKGSK3BKMT2A | |
| SCHEMBL4534752 | 0.85 | AXL (0.48) | AXLCDK8TNIKGSK3BSGK1 | |
| SCHEMBL29898600 | 0.85 | KIT (0.52) | AXLCDK8TNIKGSK3BSGK1 | |
| SCHEMBL7870634 | 0.85 | CLK1 (0.52) | AXLCDK8TNIKGSK3BSGK1 | |
| SCHEMBL12634905 | 0.83 | AXL (0.59) | AXLCDK8TNIKGSK3BSGK1 | |
| SCHEMBL27732408 | 0.81 | AXL (0.58) | AXLCDK8TNIKGSK3BSGK1 | |
| SCHEMBL7867667 | 0.81 | CAMKK2 (0.61) | AXLCDK8CAMKK2KMT2ANTRK1 | |
| SCHEMBL16932960 | 0.80 | GSK3B (0.56) | AXLCDK8TNIKGSK3BSGK1 | |
| SCHEMBL16932959 | 0.80 | GSK3B (0.56) | AXLCDK8TNIKGSK3BSGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015112854-A1 | SUBSTITUTED PYROOLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| EP-2094699-B1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI AVENTIS (FR) | 2011-07-20 | — | — | EP | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| CN-101522678-A | Novel imidazolinone derivatives, their preparation as medicaments, pharmaceutical compositions, their use as inhibitors of kinases, in particular CDC7 | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | CN | disclosed |
| WO-2008046982-A2 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | TPMT, MALT1, IRAK4 | AXL 4400/4885CDK8 800/4885TNIK 844/4885 |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | CDC7, CDK7, CDK17 | AXL 533/4885CDK8 119/4885TNIK 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.